ZIOPHARM Oncology, Inc. - Product Pipeline Review - H2 2011
Global Markets Direct
November 28, 2011 105 Pages - SKU: GMD6692204
|
|
ZIOPHARM Oncology, Inc. - Product Pipeline Review - H2 2011
Summary
Global Market Direct’s pharmaceuticals report, “ZIOPHARM Oncology, Inc. - Product Pipeline Review - H2 2011” provides data on the ZIOPHARM Oncology, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, ZIOPHARM Oncology, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from ZIOPHARM Oncology, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope - ZIOPHARM Oncology, Inc. - Brief ZIOPHARM Oncology, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ZIOPHARM Oncology, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of ZIOPHARM Oncology, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the ZIOPHARM Oncology, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy - Evaluate ZIOPHARM Oncology, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of ZIOPHARM Oncology, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the ZIOPHARM Oncology, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with ZIOPHARM Oncology, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ZIOPHARM Oncology, Inc. and identify potential opportunities in those areas.
|
- ZIOPHARM Oncology, Inc. Snapshot
- ZIOPHARM Oncology, Inc. Overview
- Key Information
- Key Facts
- ZIOPHARM Oncology, Inc. - Research and Development Overview
- Key Therapeutic Areas
- ZIOPHARM Oncology, Inc. - Pipeline Review
- Pipeline Products by Stage of Development
- Pipeline Products - Monotherapy
- Pipeline Products - Combination Treatment Modalities
- ZIOPHARM Oncology, Inc. - Pipeline Products Glance
- ZIOPHARM Oncology, Inc. Clinical Stage Pipeline Products
- Phase II Products/Combination Treatment Modalities
- Phase I Products/Combination Treatment Modalities
- ZIOPHARM Oncology, Inc.-Early Stage Pipeline Products
- Pre-Clinical Products/Combination Treatment Modalities
- ZIOPHARM Oncology, Inc. - Drug Profiles
- Zinapar + CHOP
- Product Description
- Mechanism of Action
- R&D Progress
- Zybulin + Erlotinib
- Product Description
- Mechanism of Action
- R&D Progress
- Zymafos + Adriamycin
- Product Description
- Mechanism of Action
- R&D Progress
- Zymafos Oral
- Product Description
- Mechanism of Action
- R&D Progress
- ZIOPHARM Oncology, Inc. - Pipeline Analysis
- ZIOPHARM Oncology, Inc. - Pipeline Products by Therapeutic Class
- ZIOPHARM Oncology, Inc. - Pipeline Products By Target
- ZIOPHARM Oncology, Inc. - Pipeline Products by Route of Administration
- ZIOPHARM Oncology, Inc. - Pipeline Products by Molecule Type
- ZIOPHARM Oncology, Inc. - Recent Pipeline Updates
- ZIOPHARM Oncology, Inc. - Dormant Projects
- ZIOPHARM Oncology, Inc. - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- May 31, 2009: ZIOPHARM Presents Positive Data From Phase I Study Of Palifosfamide In Combination With Doxorubicin At ASCO
- May 31, 2009: ZIOPHARM Presents Positive Data From Phase I Study Of Palifosfamide In Combination With Doxorubicin At ASCO
- May 31, 2009: ZIOPHARM Reports Positive Data From Phase I Study Of Palifosfamide In Combination With Doxorubicin
- May 31, 2009: ZIOPHARM Reports Positive Phase I Study Data Of Palifosfamide In Combination With Doxorubicin
- Jan 31, 2006: ZIOPHARM Initiates ZIO-101 Phase I/II Myeloma Study
- Aug 30, 2011: ZIOPHARM Oncology Announces First Patient Dosed In Phase I Study Of ZIN ATI-001 In Advanced Melanoma
- May 30, 2009: ZIOPHARM Presents Positive Indibulin Translational And Dose Scheduling Data At ASCO Annual Meeting
- May 30, 2009: ZIOPHARM Presents Positive Indibulin Translational And Dose Scheduling Data At ASCO Meeting 2010
- Dec 29, 2010: Ziopharm Oncology Initiates Phase I Study Of Palifosfamide In Small Cell Lung And Other Cancers
- Oct 28, 2011: ZIOPHARM Presents Promising Preclinical Pediatric Sarcoma Data With Oral And IV Palifosfamide At 2011 CTOS/MSTS Meeting
- Jun 28, 2007: ZIOPHARM Presents ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data At International Myeloma Workshop
- Sep 27, 2010: ZIOPHARM Wins Japanese Patent For Darinaparsin
- Oct 26, 2011: Solasia Initiates Darinaparsin Injection Phase I Study
- Jan 26, 2010: ZIOPHARM Receives US Patent Allowance For Important Palifosfamide Composition Zymafos
- Oct 25, 2007: Ziopharm Announces Clinical And Preclinical Data Of Oral Indibulin (ZIO-301) At AACR/NCI/EORTC Conference
- Sep 25, 2007: Data From Ongoing Hematological Trials With Darinaparsin Presents At European College Of Clinical Oncology Annual Meeting
- Sep 25, 2007: Positive ZIO-201 Interim Phase II Sarcoma Data Presents At European College Of Clinical Oncology Annual (ECCO) Meeting
- May 25, 2005: ZIOPHARM Initiates Phase I Study Of ZIO-101
- Oct 23, 2008: ZIOPHARM Presents Darinaparsin Molecular Mechanism Of Action And Preliminary Oral Administration Phase I Clinical Data At The EORTC-NCI-AACR Symposium
- Sep 23, 2010: ZIOPHARM Receives FDA Orphan Drug Designation For Darinaparsin In Treatment Of Peripheral T-cell Lymphoma
- Jul 23, 2008: ZIOPHARM Presents Safety And Preliminary Efficacy Data From Two Phase I Studies Of Indibulin At AACR Centennial Conference
- Jun 21, 2010: ZIOPHARM Provides Guidance On Planned Pivotal Phase III Study Of Palifosfamide In Metastatic Soft Tissue Sarcoma
- Jun 21, 2010: ZIOPHARM Provides Guidance On Planned Pivotal Phase III Study Of Palifosfamide In Metastatic Soft Tissue Sarcoma
- May 21, 2010: ZIOPHARM To Present Further Palifosfamide PICASSO Phase II Results In Oral Session At ASCO
- May 20, 2011: ZIOPHARM And Intrexon Announce Preclinical Study Results Of IL-12 At 2011 ASGCT Meeting
- Apr 20, 2010: ZIOPHARM Presents Preclinical Data On Darinaparsin At AACR
- Mar 20, 2008: ZIOPHARM Presents Promising Early Data From Phase Ib Study Of Indibulin At 6th International Symposium On Targeted Anticancer Therapies
- Jan 20, 2011: ZIOPHARM Receives European Positive Opinion For Orphan Drug Designation Of Darinaparsin
- Nov 19, 2010: ZIOPHARM Presents New Darinaparsin Preclinical Data At EORTC-NCI-AACR Meeting
- Oct 19, 2009: ZIOPHARM Announces Positive Palifosfamide Sarcoma Randomized Phase II Interim Data
- Jul 19, 2010: ZIOPHARM Initiates Phase III Clinical Study With Palifosfamide And Doxorubicin
- Jul 19, 2010: ZIOPHARM Initiates Phase III Clinical Trial Of Palifosfamide In Patients With Metastatic Soft Tissue Sarcoma
- Apr 19, 2005: ZIOPHARM Presents ZIO-201 Preclinical Data At AACR
- Nov 18, 2005: ZIOPHARM Oncology Announces ZIO-102 Data Presented At AACR-NCI-EORTC International Conference
- Nov 17, 2008: ZIOPHARM Oncology Presents Positive Data From Studies Of Palifosfamide
- Jan 17, 2006: ZIOPHARM Receives Notice Of Allowance On Key ZIO-101 Patent
- Nov 16, 2005: ZIOPHARM Oncology Announces ZIO-101 Phase I Data Presented At AACR-NCI-EORTC International Conference
- Apr 16, 2008: ZIOPHARM Presents Positive Data From Phase II Study Of Darinaparsin In Advanced Hematological Malignancies At AACR 2008 Annual Meeting
- Apr 16, 2007: ZIOPHARM Presents Unique Mechanism Data For Indibulin At AACR
- Oct 15, 2008: ZIOPHARM Receives Orphan Medicinal Product Designation For Palifosfamide (ZIO-201) In The Treatment Of Soft Tissue Sarcoma
- Oct 14, 2009: ZIOPHARM Announces Positive Palifosfamide Sarcoma Phase II Interim Data
- Sep 14, 2006: ZIOPHARM Presents ZIO-101 Clinical Development Strategy At European Society of Hematology Meeting
- May 13, 2011: ZIOPHARM Oncology Files Investigational New Drug Application For Ad-RTS-IL-12
- Feb 12, 2007: ZIOPHARM Presents ZIO-101 Data At Bone Marrow Transplant Meeting
- Dec 11, 2006: ZIOPHARM Presents Positive ZIO-101 Myeloma Data At ASH
- Jun 10, 2011: ZIOPHARM Oncology Announces Acceptance Of IND Application For ZIN ATI-001
- May 10, 2007: ZIOPHARM Treats First Patient In Phase II ZIO-101 Liver Cancer Trial
- Nov 09, 2006: ZIOPHARM Announces New ZIO-101 Mechanism Data At EORTC-NCI-AACR
- May 09, 2008: ZIOPHARM Receives FDA Orphan Drug Designation For Palifosfamide (ZIO-201) In The Treatment Of Soft Tissue Sarcoma
- Jan 09, 2007: ZIOPHARM Initiates ZIO-101 Phase II Study In Hematological Cancers
- Apr 08, 2010: ZIOPHARM Begins Oral Indibulin Phase I/II Trial In Breast Cancer
- Apr 08, 2010: ZIOPHARM Initiates Oral Indibulin Phase I/II Trial In Breast Cancer
- Jun 07, 2010: ZIOPHARM Presents Positive Palifosfamide Phase II Results In Oral Session At ASCO
- Jun 07, 2010: ZIOPHARM Presents Positive Palifosfamide PICASSO Phase II Results In Oral Session At ASCO 2010 Meeting
- Dec 06, 2010: ZIOPHARM Presents New Darinaparsin Preclinical Lymphoma Data At ASH Annual Meeting
- Dec 06, 2004: ZIOPHARM And The University Of Texas M.D. Anderson Cancer Center Presents Data On ZIO-102 At American Society Of Hematology Second Organic Arsenic
- Nov 06, 2009: ZIOPHARM Presents Positive Palifosfamide Sarcoma Randomized Phase II Interim Data at Annual Meeting of the Connective Tissue Oncology Society
- Nov 06, 2009: ZIOPHARM Presents Positive Palifosfamide Sarcoma Randomized Phase II Interim Data At Annual Meeting Of The Connective Tissue Oncology Society
- Sep 05, 2008: ZIOPHARM Commences Randomized Phase II Study Of Palifosfamide In Soft Tissue Sarcoma
- Apr 05, 2006: ZIOPHARM Announces ZIO-101 Anti-Cancer Activity At AACR
- Apr 05, 2005: ZIOPHARM Announces Approval Of IND For ZIO-101
- Aug 04, 2008: Leukemia Journal Publishes Results Of Darinaparsin Study
- Feb 04, 2008: ZIOPHARM Commences Treatment Of First Patients In Two Separate Phase I/II Combination Studies Of Both Indibulin And Palifosfamide
- Nov 03, 2006: ZIOPHARM Presents ZIO-201 Phase I Data At CTOS
- Oct 03, 2006: ZIOPHARM Presents ZIO-101 Phase I Solid Tumor Data
- Nov 02, 2006: Ziopharm Announces Preclinical Data Of ZIO-201 In Pediatric Cancers
- Jun 02, 2007: ZIOPHARM Presents ZIO-101 (Darinaparsin) Phase I Advanced Solid Tumor Data At ASCO
- Jun 01, 2009: ZIOPHARM Presents Positive Darinaparsin Clinical Data At ASCO's Clinical Science Symposium
- Jun 01, 2009: ZIOPHARM Reports Positive Darinaparsin Clinical Data At ASCO Annual Meeting
- Financial Deals Landscape
- ZIOPHARM Oncology, Inc., Deals Summary
- ZIOPHARM Oncology, Inc., Pharmaceuticals & Healthcare, Deal Details
- Asset Transactions
- ZIOPHARM Oncology Acquires Indibulin From Baxter Healthcare
- Venture Financing
- ZIOPHARM Raises $18 Million In Venture Financing
- Partnerships
- ZIOPHARM Oncology Enters Into Co-Development Agreement With Intrexon
- ZIOPHARM Enters Into Co-Development Agreement With Southern Research Institute
- Merger
- ZIOPHARM Merges With EasyWeb
- Licensing Agreements
- ZIOPHARM Oncology Enters Into Licensing Agreement With Solasia Pharma For Darinaparsin
- ZIOPHARM Enters Into Licensing Agreement With DEKK-TEC
- ZIOPHARM Enters Into Licensing Agreement With M. D. Anderson Cancer Center
- Equity Offering
- ZIOPHARM Oncology Completes An Underwritten Public Offering Of $63.5 Million
- ZIOPHARM Oncology Completes Underwritten Public Offering For $35 Million
- ZIOPHARM Oncology Completes Public Offering For $48 Million
- ZIOPHARM Oncology Completes Private Placement Of $5 Million
- ZIOPHARM Completes Private Placement Of $31 Million
- Ziopharm Completes Private Placement Of $37 Million
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- ZIOPHARM Oncology, Inc. - Pipeline by Therapy Area and Indication, H2 2011
- ZIOPHARM Oncology, Inc. - Pipeline by Stage of Development, H2 2011
- ZIOPHARM Oncology, Inc. - Monotherapy Products in Pipeline, H2 2011
- ZIOPHARM Oncology, Inc. - Combination Treatment Modalities in Pipeline, H2 2011
- ZIOPHARM Oncology, Inc. - Phase II, H2 2011
- ZIOPHARM Oncology, Inc. - Phase I, H2 2011
- ZIOPHARM Oncology, Inc. - Pipeline By Therapeutic Class, H2 2011
- ZIOPHARM Oncology, Inc. - Pipeline By Target, H2 2011
- ZIOPHARM Oncology, Inc. - Pipeline By Route of Administration, H2 2011
- ZIOPHARM Oncology, Inc. - Pipeline By Molecule Type, H2 2011
- ZIOPHARM Oncology, Inc. - Recent Pipeline Updates, H2 2011
- ZIOPHARM Oncology, Inc. - Dormant Developmental Projects, 2010
- ZIOPHARM Oncology, Inc., Other Locations
- ZIOPHARM Oncology, Inc., Deals Summary
- ZIOPHARM Oncology Acquires Indibulin From Baxter Healthcare
- ZIOPHARM Raises $18 Million In Venture Financing
- ZIOPHARM Oncology Enters Into Co-Development Agreement With Intrexon
- ZIOPHARM Enters Into Co-Development Agreement With Southern Research Institute
- ZIOPHARM Merges With EasyWeb
- ZIOPHARM Oncology Enters Into Licensing Agreement With Solasia Pharma For Darinaparsin
- ZIOPHARM Enters Into Licensing Agreement With DEKK-TEC
- ZIOPHARM Enters Into Licensing Agreement With M. D. Anderson Cancer Center
- ZIOPHARM Oncology Completes An Underwritten Public Offering Of $63.5 Million
- ZIOPHARM Oncology Completes Underwritten Public Offering For $35 Million
- ZIOPHARM Oncology Completes Public Offering For $48 Million
- ZIOPHARM Oncology Completes Private Placement Of $5 Million
- ZIOPHARM Completes Private Placement Of $31 Million
- Ziopharm Completes Private Placement Of $37 Million
- List of Figures
- ZIOPHARM Oncology, Inc. - Pipeline by Therapy Area and Indication, H2 2011
- ZIOPHARM Oncology, Inc. - Pipeline by Stage of Development, H2 2011
- ZIOPHARM Oncology, Inc. - Monotherapy Products in Pipeline, H2 2011
- ZIOPHARM Oncology, Inc. - Combination Treatment Modalities in Pipeline, H2 2011
- ZIOPHARM Oncology, Inc. - Pipeline By Therapeutic Class, H2 2011
- ZIOPHARM Oncology, Inc. - Pipeline By Target, H2 2011
- ZIOPHARM Oncology, Inc. - Pipeline By Route of Administration, H2 2011
- ZIOPHARM Oncology, Inc. - Pipeline By Molecule Type, H2 2011
Share this report
Other tasks Related Markets Pharmaceuticals Company Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
